Cargando…

Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study

BACKGROUND: Vaccines for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being promoted worldwide. In this study, we analyzed the relationship between adverse reactions and the profile of vaccinated recipients. METHODS: Vaccinated subjec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urakawa, Ryuta, Isomura, Emiko Tanaka, Matsunaga, Kazuhide, Kubota, Kazumi, Ike, Miho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864597/ https://www.ncbi.nlm.nih.gov/pubmed/35197017 http://dx.doi.org/10.1186/s12879-022-07175-y

Ejemplares similares

Young Age, Female Sex, and No Comorbidities Are Risk Factors for Adverse Reactions after the Third Dose of BNT162b2 COVID-19 Vaccine against SARS-CoV-2: A Prospective Cohort Study in Japan
por: Urakawa, Ryuta, et al.
Publicado: (2022)

Multivariate Analysis of Adverse Reactions and Recipient Profiles in COVID-19 Booster Vaccinations: A Prospective Cohort Study
por: Urakawa, Ryuta, et al.
Publicado: (2023)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Adverse events after BNT162b2 mRNA COVID-19 vaccination in health care workers and medical students in Japan
por: Namiki, Takahiro, et al.
Publicado: (2022)

Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea
por: Lee, Yun Woo, et al.
Publicado: (2021)

Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy
por: Inoue, Sumito, et al.
Publicado: (2022)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

DIAPHRAGMATIC PARALYSIS FOLLOWING SECOND DOSE OF THE BNT162B2 MRNA COVID-19 VACCINE
por: PRUDENTI, JOHN A, et al.
Publicado: (2022)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses
por: Braun, Eyal, et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

General Factors and Dental-Related Risk Factors for Postoperative Pneumonia or Infectious Complications: A Retrospective Study
por: Isomura, Emiko Tanaka, et al.
Publicado: (2023)

Markers of Memory CD8 T Cells Depicting the Effect of the BNT162b2 mRNA COVID-19 Vaccine in Japan
por: Kondo, Hiroyuki, et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
por: Markewitz, Robert, et al.
Publicado: (2022)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

The Limited Effect of a History of COVID-19 on Antibody Titers and Adverse Reactions Following BNT162b2 Vaccination: A Single-Center Prospective Study
por: Kushima, Hisako, et al.
Publicado: (2022)

Colitis with Hypereosinophilia following the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine: A Case Report with a Literature Review
por: Doman, Tsuyoshi, et al.
Publicado: (2022)

Antibody responses to BNT162b2 mRNA COVID-19 vaccine in healthcare workers and patients with urological diseases in Japan
por: Hatakeyama, S., et al.
Publicado: (2022)

Psoriatic arthritis flare-up after a second dose of BNT162b2 COVID-19 mRNA vaccine
por: Watabe, Daisuke, et al.
Publicado: (2022)

Re: ‘Association between IgG antibody levels and adverse events after first and second BNT162b2 mRNA vaccine doses’ by Braun et al
por: Zhou, Yuchi, et al.
Publicado: (2022)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan
por: Matsumoto, Naomi, et al.
Publicado: (2023)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
por: Terashima, Takeshi
Publicado: (2021)

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022)

Central serous chorioretinopathy following the BNT162b2 mRNA vaccine
por: Hanhart, J., et al.
Publicado: (2022)

Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

A novel adverse effect of the BNT162b2 mRNA vaccine: First episode of acute mania with psychotic features
por: Yesilkaya, Umit Haluk, et al.
Publicado: (2021)

Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan
por: Kageyama, Takahiro, et al.
Publicado: (2021)

Before and After: Attitude and Adverse Effects Induced by the First and Second Doses of mRNA BNT162b2 Vaccine among Healthcare Professionals in the First Weeks after Their Introduction in Poland
por: Pasternak, Gerard, et al.
Publicado: (2023)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
por: Naito, Toshio, et al.
Publicado: (2021)

Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study
por: Kang, Yu Min, et al.
Publicado: (2021)

Antibody Response After a Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Liver Transplant Recipients
por: Sakai, Akiyoshi, et al.
Publicado: (2022)

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3fpdjj3sv10nvtjqa4k0unpmfu